1. Home
  2. ARKO vs CINGW Comparison

ARKO vs CINGW Comparison

Compare ARKO & CINGW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARKO
  • CINGW
  • Stock Information
  • Founded
  • ARKO 1970
  • CINGW N/A
  • Country
  • ARKO United States
  • CINGW United States
  • Employees
  • ARKO N/A
  • CINGW 13
  • Industry
  • ARKO Oil Refining/Marketing
  • CINGW Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARKO Energy
  • CINGW Health Care
  • Exchange
  • ARKO Nasdaq
  • CINGW Nasdaq
  • Market Cap
  • ARKO N/A
  • CINGW N/A
  • IPO Year
  • ARKO N/A
  • CINGW 2021
  • Fundamental
  • Price
  • ARKO $6.56
  • CINGW $0.05
  • Analyst Decision
  • ARKO Hold
  • CINGW
  • Analyst Count
  • ARKO 2
  • CINGW 0
  • Target Price
  • ARKO $6.13
  • CINGW N/A
  • AVG Volume (30 Days)
  • ARKO 273.4K
  • CINGW N/A
  • Earning Date
  • ARKO 11-07-2024
  • CINGW N/A
  • Dividend Yield
  • ARKO 1.83%
  • CINGW N/A
  • EPS Growth
  • ARKO N/A
  • CINGW N/A
  • EPS
  • ARKO 0.16
  • CINGW N/A
  • Revenue
  • ARKO $8,973,013,000.00
  • CINGW N/A
  • Revenue This Year
  • ARKO N/A
  • CINGW N/A
  • Revenue Next Year
  • ARKO $1.60
  • CINGW N/A
  • P/E Ratio
  • ARKO $41.46
  • CINGW N/A
  • Revenue Growth
  • ARKO N/A
  • CINGW N/A
  • 52 Week Low
  • ARKO $4.09
  • CINGW N/A
  • 52 Week High
  • ARKO $8.42
  • CINGW N/A
  • Technical
  • Relative Strength Index (RSI)
  • ARKO 44.46
  • CINGW N/A
  • Support Level
  • ARKO $6.40
  • CINGW N/A
  • Resistance Level
  • ARKO $6.91
  • CINGW N/A
  • Average True Range (ATR)
  • ARKO 0.27
  • CINGW 0.00
  • MACD
  • ARKO -0.03
  • CINGW 0.00
  • Stochastic Oscillator
  • ARKO 17.58
  • CINGW 0.00

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: